title: Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.
authors.affiliation: Department of Hematology, Erasmus MC Cancer Institute (EMC), Rotterdam, the Netherlands a.broyl@erasmusmc.nl.
authors.forename: Annemiek
authors.initials: A
authors.lastname: Broijl
authors.affiliation: Department of Hematology, Academic Medical Center (AMC), Amsterdam, the Netherlands.
authors.forename: Marie-José
authors.initials: MJ
authors.lastname: Kersten
authors.affiliation: HOVON Data Center, Erasmus MC Cancer Institute (EMC), Rotterdam, the Netherlands.
authors.forename: Wendimagegn Ghidey
authors.initials: WG
authors.lastname: Alemayehu
authors.affiliation: Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands.
authors.forename: Mark-David
authors.initials: MD
authors.lastname: Levin
authors.affiliation: Department of Hematology, Antonius Hospital, Nieuwegein, the Netherlands.
authors.forename: Okke
authors.initials: O
authors.lastname: de Weerdt
authors.affiliation: Department of Hematology, University Medical Center (UMCG), Groninge, the Netherlands.
authors.forename: Edo
authors.initials: E
authors.lastname: Vellenga
authors.affiliation: Department of Hematology, VU medical center, Amsterdam (VUmc), the Netherlands.
authors.forename: Ellen
authors.initials: E
authors.lastname: Meijer
authors.affiliation: Department of Hematology, Meander Medical Center, Amersfoort, the Netherlands.
authors.forename: Shulamit
authors.initials: S
authors.lastname: Wittebol
authors.affiliation: Department of Internal Medicine, Groene Hart Ziekenhuis, Gouda, the Netherlands.
authors.forename: Bea C
authors.initials: BC
authors.lastname: Tanis
authors.affiliation: HOVON Data Center, Erasmus MC Cancer Institute (EMC), Rotterdam, the Netherlands.
authors.forename: Petra B
authors.initials: PB
authors.lastname: Cornelisse
authors.affiliation: Working group on Hemato-Oncologic Genome Diagnostics (WHGD), Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.
authors.forename: Marian
authors.initials: M
authors.lastname: Stevens-Kroef
authors.affiliation: Department of Hematology, University Hospital, Maastricht, the Netherlands.
authors.forename: Gerard M J
authors.initials: GM
authors.lastname: Bos
authors.affiliation: Department of Hematology, HAGA Hospital, the Hague, the Netherlands.
authors.forename: Pierre W
authors.initials: PW
authors.lastname: Wijermans
authors.affiliation: Department of Hematology, VU medical center, Amsterdam (VUmc), the Netherlands.
authors.forename: Henk
authors.initials: H
authors.lastname: Lokhorst
authors.affiliation: Department of Hematology, Erasmus MC Cancer Institute (EMC), Rotterdam, the Netherlands.
authors.forename: Pieter
authors.initials: P
authors.lastname: Sonneveld
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069286:Bortezomib / Q000627:therapeutic use*; D003907:Dexamethasone / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D054796:Drug Dosage Calculations; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D016015:Logistic Models; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D016609:Neoplasms, Second Primary / Q000150:complications / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D012008:Recurrence; D016019:Survival Analysis; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D000077269:Lenalidomide
keywords: VRD; escalated dose; first relapse; multiple myeloma